117 related articles for article (PubMed ID: 11038453)
1. First trimester biochemical screening for Down syndrome: free beta hCG versus intact hCG.
Hallahan T; Krantz D; Orlandi F; Rossi C; Curcio P; Macri S; Larsen J; Buchanan P; Macri J
Prenat Diagn; 2000 Oct; 20(10):785-9;discussion 790-1. PubMed ID: 11038453
[TBL] [Abstract][Full Text] [Related]
2. Free beta-hCG subunit versus intact hCG in Down syndrome screening.
Wenstrom KD; Owen J; Chu DC; Boots L
Obstet Gynecol; 1997 Sep; 90(3):370-4. PubMed ID: 9277646
[TBL] [Abstract][Full Text] [Related]
3. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
4. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
5. Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
Spencer K; Talbot JA; Abushoufa RA
Prenat Diagn; 2002 Aug; 22(8):656-62. PubMed ID: 12210572
[TBL] [Abstract][Full Text] [Related]
6. Total hCG versus free beta-hCG combined with alpha-fetoprotein for Down syndrome screening in Taiwan.
Hsieh TT; Hsu JJ; Cheng PJ; Lee CN; Jou HJ; Chen CP
Taiwan J Obstet Gynecol; 2007 Sep; 46(3):230-5. PubMed ID: 17962101
[TBL] [Abstract][Full Text] [Related]
7. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
Hu Z; Liu X; Li L; Jia C; Li D; Liu R
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
[TBL] [Abstract][Full Text] [Related]
8. hCG and the free beta-subunit as screening tests for Down syndrome.
Knight GJ; Palomaki GE; Neveux LM; Fodor KK; Haddow JE
Prenat Diagn; 1998 Mar; 18(3):235-45. PubMed ID: 9556040
[TBL] [Abstract][Full Text] [Related]
9. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
Spencer K
Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
[TBL] [Abstract][Full Text] [Related]
10. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
[TBL] [Abstract][Full Text] [Related]
11. The use of free beta-hCG in antenatal screening for Down's syndrome.
Wald N; Densem J; Stone R; Cheng R
Br J Obstet Gynaecol; 1993 Jun; 100(6):550-7. PubMed ID: 7687460
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum markers in first-trimester down syndrome screening.
Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
[TBL] [Abstract][Full Text] [Related]
13. Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks.
Macintosh MC; Iles R; Teisner B; Sharma K; Chard T; Grudzinskas JG; Ward RH; Muller F
Prenat Diagn; 1994 Mar; 14(3):203-8. PubMed ID: 7519773
[TBL] [Abstract][Full Text] [Related]
14. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
15. Modeling Down syndrome screening performance using first-trimester serum markers.
Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
[TBL] [Abstract][Full Text] [Related]
16. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
17. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
[TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-risk assessment of fetal trisomy 21 including total human choriogonadotropin (hCG) or its free beta-subunit (free beta hCG).
Sancken U; Bahner D
Fetal Diagn Ther; 2003; 18(2):122-7. PubMed ID: 12576748
[TBL] [Abstract][Full Text] [Related]
19. Appropriate biochemical parameters in first-trimester screening for Down syndrome.
Cuckle HS; van Lith JM
Prenat Diagn; 1999 Jun; 19(6):505-12. PubMed ID: 10416963
[TBL] [Abstract][Full Text] [Related]
20. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
